Polyrizon secures GMP manufacturing partnership for PL-14 clinical trial

Polyrizon, a company focused on developing allergy solutions, has announced its collaboration with Eurofins CDMO Amatsiaquitaine S.A.S for the manufacturing of Clinical Trial Material (CTM) for its PL-14 allergy blocker. This agreement provides Polyrizon with access to a reliable EU-based GMP manufacturing facility, which has large-scale commercial production capabilities. The production will support the preparation for a clinical trial anticipated to start in 2025. Tomer Izraeli, the CEO of Polyrizon, expressed his satisfaction with the partnership, which he believes significantly bolsters their efforts in providing effective allergy protection. Polyrizon aims to utilize its proprietary hydrogel technology, based on naturally occurring building blocks, delivered in nasal spray form to create a containment barrier in the nasal cavity as a potential treatment for allergies. This partnership marks a pivotal step in their development plan, demonstrating Polyrizon’s commitment to advancing their innovative approaches and assuring compliance with manufacturing standards required for their clinical studies. The collaboration is expected to streamline the preparation and ensure the availability of the necessary materials for the upcoming trial, thereby enhancing their operational efficiency. The company’s focus on allergy treatments is underscored by the necessity of effective solutions for allergy sufferers globally, particularly in light of increasing allergy prevalence and the substantial unmet need for novel therapeutic options. As they prepare for this trial, it continues to be crucial for the company to align their resources effectively to overcome the challenges associated with clinical development and regulatory compliance.